We’re delighted to share that LinkGevity, a company based here at Babraham Research Campus, has been prominently featured in The Times for their pioneering work in longevity science. Founded by sisters Dr Carina Kern and Serena Kern-Libera, the company is developing what could become the first drug to target ageing by preventing necrosis, a key form of unregulated cell death.

Working from their labs on Campus, LinkGevity has generated highly promising preclinical results, showing that their approach can protect cells from degeneration. Independent labs have replicated their findings, and human clinical trials are expected to begin soon, starting with applications in kidney health. Their work has already attracted significant backing from billionaire investors, leading scientists, the Francis Crick Institute, Innovate UK, the European Union, and NASA, with the latter selecting LinkGevity as the only UK company in its global space health programme.

The article highlights not only the scientific ambition of the team, but also their commitment to improving healthy ageing rather than pursuing extreme longevity. As Serena puts it, their mission is to prevent the loss of human dignity associated with degenerative disease, an ambition that resonates strongly with the translational science ethos that defines our Campus.

Read the full article for deeper insights into their science, inspiration, and future plans.